Uptake of tumour necrosis factor – alpha inhibitor biosimilars for psoriasis: A drug utilisation study from BADBIR
BJD, 2023.
Phan DB, Bewley AP, Smith CH, Mackenzie T, Griffiths CEM, Lunt M, Warren RB, Yiu ZZN; BADBIR Study Group.
Read publication: BJD
Related
Biosimilars for the Treatment of Psoriasis A Systematic Review of Clinical Trials and Observational ...
Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000...
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective c...
0 Comments